Clin2
NCT07699471Likely a fitRecruiting

Study of a new drug for adults with low parathyroid hormone

Hypoparathyroidism

Part of Hormones & metabolism clinical trials.

This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
160 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have had hypoparathyroidism for at least 12 months, either after thyroid surgery or from other causes like genetics or autoimmune disease.
  • You are currently taking at least 0.5 micrograms of calcitriol (a form of vitamin D) or 1.0 micrograms of alfacalcidol each day, plus at least 1000 milligrams of calcium (from supplements) for the past 12 weeks, with stable doses for the last 3 weeks.
  • Your blood calcium level (adjusted for protein) has been between 7.8 and 9.4 mg/dL on two tests taken at least one week apart.
  • You have not used any other parathyroid hormone drugs (like PTH 1-84 or 1-34) in the last 5 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07081997Recruiting· Phase 3
Higher-dose palopegteriparatide for hypoparathyroidism

This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.

Greeley, Colorado
NCT07706764Recruiting· Phase 3
Testing a new treatment for teens with long-term hypoparathyroidism

This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.

Bron
NCT06445036Not yet recruiting
Treatment for low blood calcium from hypoparathyroidism

This trial tests a new treatment to help people with hypoparathyroidism (a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels) manage their calcium better. It aims to reduce the need for calcium and vitamin D supplements.

Sfax, Tunisia
NCT06961071Recruiting· Phase 1/Phase 2
Parathyroid transplant for low parathyroid hormone

This trial tests whether a donated parathyroid gland can help people with low parathyroid hormone (hypoparathyroidism) control their calcium levels and reduce symptoms. Participants will receive transplant and short-term immune-suppressing drugs.

San Francisco, California
NCT06988670Recruiting· Phase 2
Testing EXT608 for adults with hypoparathyroidism

This trial tests a new medicine called EXT608 for adults with hypoparathyroidism. It aims to see if this medicine can help manage calcium levels better than current treatments.

Buenos Aires, Buenos Aires F.D.
NCT07805356Recruiting· Phase 3
Study of encaleret for chronic hypoparathyroidism

This study tests a new medicine called encaleret for people with chronic hypoparathyroidism, a condition where the body has too little parathyroid hormone, leading to low calcium levels. The medicine aims to improve calcium balance and reduce the need for daily calcium and vitamin D supplements.

Reno, Nevada

Hear when a new Hypoparathyroidism trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.